Clinical trials: Leishmaniasis, Cutaneous
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Post Kala Azar Dermal Leishmaniasis
Miltefosine for Children With PKDL
Hypothesis: Primary hypothesis: 1. Oral treatment with Miltefosine in children with PKDL at allometric daily dose (based on body weight and height) for 12 weeks is safe with a cure rate of ≥95%. Secondary hypothesis: 2.
- Trial name
- NCT02193022
- Testing
- Miltefosine
- Where
- Bangladesh
- Volunteers
- 80 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Old World Cutaneous Leishmaniasis
Randomised Clinical Trial in Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan
A four (4) -arm randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous…
- Trial name
- NCT04268524
- Testing
- drug: miltefosine with thermotherapy
- Where
- 3 sites in Pakistan
- Volunteers
- 645 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Cutaneous Leishmaniasis
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396
The primary objective of this protocol is to treat laboratory confirmed cutaneous leishmaniasis with WR 279,396 in military health care beneficiaries.
- Trial name
- NCT00657917
- Testing
- Paromomycin +Gentamicin topical cream
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
The proposed study encompasses a two-step approach. The first aiming to determine the safety of Topical 3% Amphotericin B Cream when applied three or two times per day for 4 weeks in subjects with un-complicated Cutaneous…
- Trial name
- Anfoleish (NCT01845727)
- Testing
- Topical Amphotericin B at 3%
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Cutaneous Leishmaniasis
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
"Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis " has begun in October 2008 at the Laboratory of…
- Trial name
- NCT01301924
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Oswaldo Cruz Foundation
Cutaneous Leishmaniasis
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
This study will test the ability of the topical cream WR 279,396 to treat the skin lesions caused by the parasite called leishmania. WR 279,396 is an antibiotic preparation that contains paromomycin + gentamicin.
- Trial name
- NCT00606580
- Testing
- WR 279,396 topical cream, Paromomycin Alone topical cream
- Where
- Tunisia
- Volunteers
- 375 people
- Sponsor
- U.S. Army Medical Research and Development Command
Cutaneous Leishmaniasis
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
The purpose of this study is to determine whether adding pentoxifylline to treatment of American cutaneous leishmaniasis with meglumine antimoniate increases the rate and speed of clinical response without diminishing safety, and…
- Trial name
- GT (NCT01464242)
- Testing
- Meglumine antimonate, Pentoxifylline
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Cutaneous Leishminiasis
Comparison of Intralesional Glucantime With and Without Fractional CO₂ Laser in Adults With Cutaneous Leishmaniasis
Cutaneous leishmaniasis is a common parasitic skin disease causing chronic ulcerative lesions and scarring. Intralesional meglumine antimoniate (Glucantime) is a widely used treatment; however, healing may be prolonged and…
- Trial name
- NCT07652021
- Testing
- Meglumine Antimoniate, Fractional CO₂ laser
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Combined military hospital Peshawar
Cutaneous Leishmaniasis
Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
The purpose of this trial is to determine the efficacy and safety of a combined therapy using thermotherapy (TT) (one session, 50 degrees Celsius for 30") + miltefosine at a standard dose of 2.5 mg/kg/day for 21 days for the…
- Trial name
- NCT02687971
- Testing
- Miltefosine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 130 people
- Sponsor
- Drugs for Neglected Diseases
Cutaneous Leishmaniasis
Surveillance for Leishmaniasis Skin Lesions in Mali
This study will examine why some people who become infected with the leishmaniasis parasite develop skin lesions and others do not. The parasite that causes leishmaniasis is transmitted by the bite of a sandfly.
- Trial name
- NCT00344084
- Where
- Mali
- Volunteers
- 1,593 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leishmaniasis, Mucocutaneous
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
The purpose of this study is to evaluate the safety of the Leish-111f + MPL-SE vaccine given as three injections every 28 days at each of three dose levels of Leish-111f protein, in combination with standard pentavalent antimony…
- Trial name
- NCT00111514
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- 2 sites in Peru
- Volunteers
- 48 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leishmaniasis, American
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
Cure rate for L braziliensis bolivian CL has been 70%-80% for standard systemic and local monotherapies. It would benefit patients if cure rates could be consistently >90%, so testing a combination of two treatments is proposed.
- Trial name
- NCT03829917
- Testing
- Miltefosine and Paromomycin, miltefosine, paromomycin
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Leishmaniasis
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.
- Trial name
- NCT03009422
- Testing
- Local application pentostam, intra-lisional pentostam, fractional CO2 laser
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Leishmaniasis, Cutaneous
Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis
This is an expanded access treatment protocol designed to provide a topical cream treatment option to military health care beneficiaries with parasitologically confirmed uncomplicated Cutaneous Leishmaniasis.
- Trial name
- NCT01641796
- Testing
- Paromomycin
- Where
- 2 sites in United States
- Sponsor
- U.S. Army Medical Research and Development Command
Leishmaniasis, Cutaneous
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 15 different species of the protozoan parasite Leishmania.
- Trial name
- Curaleish (NCT04072874)
- Testing
- Experimental topical (Curaleish Topical)
- Where
- Colombia
- Sponsor
- Universidad de Antioquia